Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Don Owens, Deputy Director of Communications
w. (202) 588-7767

Karilyn Gower, Press Officer
w. (202) 588-7779

David Rosen, Press Officer, Regulatory Affairs
w. (202) 588-7742

Nicholas Florko, Communications Officer, Global Trade Watch
w. (202) 454-5108

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog

Follow us on Twitter


June 13, 2013

NIH Censoring Expert to Prevent Criticism of Ethically Questionable NIH-Funded Study on Premature Infants

Agency Should Encourage Open, Evidence-Based Debates to Improve Safety of Studies, Public Citizen Says in Letter

WASHINGTON, D.C. – The National Institutes of Health (NIH) should not censor one of its experts just because he might criticize ethical lapses in an increasingly high-profile study carried out on premature babies, Public Citizen wrote today in a letter to Health and Human Services Secretary Kathleen Sebelius.

Dr. Charles Natanson, senior investigator and chief of the anesthesia section in the NIH Clinical Center’s Critical Care Medicine Department, was invited by Bloomberg BNA to co-present an educational webinar in July regarding the SUPPORT study, a NIH-funded experiment that Public Citizen recently exposed as having risked the lives of premature infants without proper parental consent. Natanson is one of the world’s leading experts on safely designing clinical trials testing treatments in critically ill patients that are usually adjusted across a wide range — for example, oxygen therapy — and measuring death as one of the primary endpoints, as was the case with this study.

In response to the invitation request from Bloomberg BNA for Natanson to participate, NIH Public Affairs Specialist Renate Myles wrote, “We are declining participation in the webinar at this time due to a forthcoming public meeting announced by HHS on [institutional review board] process for trials randomizing participants within the standard of care.”

“We are dismayed by the hypocrisy that NIH has sought to gag a renowned expert such as Dr. Natanson, who has identified serious concerns about the ethics of the study design used for the SUPPORT study,” wrote Drs. Michael Carome and Sidney Wolfe, director and senior advisor/founder of Public Citizen’s Health Research Group, respectively, in their letter, “while at the same time allowing other NIH officials the freedom to speak publicly about the study as long as their position is favorable to the NIH party line.” The letter is available at http://www.citizen.org/hrg2135.

Their letter points to a commentary piece defending the SUPPORT study that was published in the New England Journal of Medicine last week by the NIH director and two senior colleagues, including the director of the NIH institute that funded the study.

“This concerted effort by NIH officials to publicly promote a one-sided, biased defense of the study and to suppress an alternative viewpoint voiced by a well-informed NIH expert ultimately undermines the mission and integrity of the agency,” Public Citizen’s letter says.

Public Citizen urges Sebelius to immediately investigate NIH’s policies regarding participation of agency scientists in legitimate public forums and direct NIH to stop censoring experts who have well-reasoned, evidence-based critiques of the SUPPORT study or any other NIH-funded research and allow Natanson to participate in the webinar.

Information about the ethical problems with the SUPPORT study is available at http://www.citizen.org/support-study.


Copyright © 2016 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.


To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.